{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:21:43Z","timestamp":1792682503663,"version":"4.5.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"am","delay-in-days":356,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000190","name":"University of Alberta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 DK34989"],"award-info":[{"award-number":["P30 DK34989"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009680","name":"Yale Liver Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009680","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.cgh.2023.03.019","type":"journal-article","created":{"date-parts":[[2023,3,25]],"date-time":"2023-03-25T15:06:35Z","timestamp":1679756795000},"page":"2100-2109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Update in the Treatment of the Complications of Cirrhosis"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3421-937X","authenticated-orcid":false,"given":"Juan G.","family":"Abraldes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Caraceni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Ghabril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guadalupe","family":"Garcia-Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2023.03.019_bib1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis. A systematic review of 118 studies","volume":"44","author":"D'Amico","year":"2006","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.03.019_bib2","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/apt.12721","article-title":"Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients","volume":"39","author":"D'Amico","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2023.03.019_bib3","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2007.05.024","article-title":"Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis","volume":"133","author":"Ripoll","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.03.019_bib4","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jhep.2022.07.004","article-title":"Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design","volume":"77","author":"Allen","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.03.019_bib5","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/ajg.2013.110","article-title":"Mortality risk according to different clinical characteristics of first episode of liver decompensation in cirrhotic patients: a nationwide, prospective, 3-year follow-up study in Italy","volume":"108","author":"Bruno","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.03.019_bib6","first-page":"CD011510","article-title":"Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices","volume":"10","author":"Zacharias","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cgh.2023.03.019_bib7","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(18)31875-0","article-title":"Beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial","volume":"393","author":"Villanueva","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.03.019_bib8","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.03.019_bib9","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1002\/hep.28824","article-title":"Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: the \u201cAnticipate\u201d study","volume":"64","author":"Abraldes","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.03.019_bib10","doi-asserted-by":"crossref","first-page":"723","DOI":"10.14309\/ajg.0000000000000994","article-title":"Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease","volume":"116","author":"Pons","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.03.019_bib11","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1002\/hep4.2091","article-title":"Noninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: validation of ANTICIPATE models and development of a lab-based model","volume":"6","author":"Rabiee","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cgh.2023.03.019_bib12","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/apt.12634","article-title":"Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis","volume":"39","author":"Sinagra","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2023.03.019_bib13","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/0016-5085(81)90144-X","article-title":"The course of patients after variceal hemorrhage","volume":"80","author":"Graham","year":"1981","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.03.019_bib14","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1053\/jhep.2003.50385","article-title":"Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators","volume":"38","author":"D'Amico","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.03.019_bib15","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1053\/j.gastro.2013.10.018","article-title":"A\u00a0MELD-based model to determine risk of mortality among patients with acute variceal bleeding","volume":"146","author":"Reverter","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.03.019_bib16","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/hep.20386","article-title":"Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding","volume":"40","author":"Monescillo","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.03.019_bib17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2012.08.020","article-title":"Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study","volume":"58","author":"Garcia-Pagan","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.03.019_bib18","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/jgh.15714","article-title":"Does preemptive transjugular intrahepatic portosystemic shunt improve survival after acute variceal bleeding? Systematic review, meta-analysis, and trial sequential analysis of randomized trials","volume":"37","author":"Hussain","year":"2022","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.03.019_bib19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1053\/j.gastro.2020.09.026","article-title":"Effects of early placement of transjugular portosystemic shunts in patients with high-risk acute variceal bleeding: a meta-analysis of individual patient data","volume":"160","author":"Nicoar\u0103-Farc\u0103u","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.03.019_bib20","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/j.cgh.2021.07.018","article-title":"North American practice-based recommendations for transjugular intrahepatic portosystemic shunts in portal hypertension","volume":"20","author":"Boike","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.03.019_bib21","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1136\/gutjnl-2017-314634","article-title":"Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial","volume":"67","author":"Lv","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2023.03.019_bib22","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/hep.1840020518","article-title":"Propranolol in the treatment of portal hypertension: a caution","volume":"2","author":"Conn","year":"1982","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.03.019_bib23","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.23775","article-title":"Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites","volume":"52","author":"Serste","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.03.019_bib24","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1136\/gutjnl-2011-301348","article-title":"The window hypothesis: haemodynamic and non-haemodynamic effects of beta-blockers improve survival of patients with cirrhosis during a window in the disease","volume":"61","author":"Krag","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2023.03.019_bib25","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.cgh.2016.01.012","article-title":"Nonselective beta-blockers and survival in patients with cirrhosis and ascites: a systematic review and meta-analysis","volume":"14","author":"Chirapongsathorn","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.03.019_bib26","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s12072-019-09986-9","article-title":"Treatment with carvedilol improves survival of patients with acute-on-chronic liver failure: a randomized controlled trial","volume":"13","author":"Kumar","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.cgh.2023.03.019_bib27","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/apt.15439","article-title":"Systemic arterial blood pressure determines the therapeutic window of non-selective beta blockers in decompensated cirrhosis","volume":"50","author":"Tergast","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2023.03.019_bib28","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.cgh.2021.01.027","article-title":"AGA clinical practice update on management of bleeding gastric varices: expert review","volume":"19","author":"Henry","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.03.019_bib29","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1001\/jamasurg.2019.0407","article-title":"Management options for gastric variceal hemorrhage","volume":"154","author":"Lee","year":"2019","journal-title":"JAMA Surg"},{"key":"10.1016\/j.cgh.2023.03.019_bib30","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1002\/hep.31718","article-title":"Endoscopic cyanoacrylate injection versus balloon-occluded retrograde transvenous obliteration for prevention of gastric variceal bleeding: a randomized controlled trial","volume":"74","author":"Luo","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.03.019_bib31","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2021.04.022","article-title":"Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis","volume":"75","author":"Villanueva","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.03.019_bib32","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/hep.31884","article-title":"Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases","volume":"74","author":"Biggins","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.03.019_bib33","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jhep.2018.03.024","article-title":"EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.03.019_bib34","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1111\/liv.12583","article-title":"Adherence to a moderate sodium restriction diet in outpatients with cirrhosis and ascites: a real-life cross-sectional study","volume":"35","author":"Morando","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2023.03.019_bib35","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.3748\/wjg.v20.i10.2704","article-title":"TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis","volume":"20","author":"Bai","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.03.019_bib36","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1053\/j.gastro.2016.09.016","article-title":"Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites","volume":"152","author":"Bureau","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.03.019_bib37","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/S0140-6736(18)30840-7","article-title":"Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial","volume":"391","author":"Caraceni","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.03.019_bib38","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jhep.2018.08.006","article-title":"Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial","volume":"69","author":"Sola","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.03.019_bib39","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/hep.24786","article-title":"Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials","volume":"55","author":"Bernardi","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.03.019_bib40","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jhep.2011.04.027","article-title":"Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study","volume":"56","author":"Singh","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.03.019_bib41","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/ajg.2013.9","article-title":"Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study","volume":"108","author":"Singh","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.03.019_bib42","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1136\/flgastro-2022-102128","article-title":"Palliative long-term abdominal drains for the management of refractory ascites due to cirrhosis: a consensus document","volume":"13","author":"Macken","year":"2022","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.cgh.2023.03.019_bib43","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/apt.15502","article-title":"Systematic review with meta-analysis: automated low-flow ascites pump therapy for refractory ascites","volume":"50","author":"Lepida","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2023.03.019_bib44","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/j.jhep.2021.01.024","article-title":"The search for disease-modifying agents in decompensated cirrhosis: from drug repurposing to drug discovery","volume":"75","author":"Caraceni","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.03.019_bib45","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/hep.32329","article-title":"The digital transformation of hepatology: the patient is logged in","volume":"75","author":"Wu","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.03.019_bib46","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.jhep.2014.12.029","article-title":"Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites","volume":"62","author":"Angeli","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.03.019_bib47","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.27709","article-title":"Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial","volume":"62","author":"Cavallin","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.03.019_bib48","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa2008290","article-title":"Terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome","volume":"384","author":"Wong","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.03.019_bib49","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jhep.2012.01.012","article-title":"Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study","volume":"56","author":"Singh","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.03.019_bib50","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/hep.30208","article-title":"Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure","volume":"71","author":"Arora","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.03.019_bib51","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/hep.28396","article-title":"Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study","volume":"63","author":"Cavallin","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.03.019_bib52","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1478-3231.2009.02182.x","article-title":"The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study","volume":"30","author":"Trawale","year":"2010","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2023.03.019_bib53","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/hep.27210","article-title":"Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver","volume":"60","author":"Vilstrup","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.03.019_bib54","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jhep.2022.06.001","article-title":"EASL Clinical Practice Guidelines on the management of hepatic encephalopathy","volume":"77","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.03.019_bib55","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.jhep.2020.07.013","article-title":"Hepatic encephalopathy: novel insights into classification, pathophysiology and therapy","volume":"73","author":"Rose","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.03.019_bib56","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.cgh.2015.11.018","article-title":"Fasting blood ammonia predicts risk and frequency of hepatic encephalopathy episodes in patients with cirrhosis","volume":"14","author":"Vierling","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.03.019_bib57","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1016\/j.jhep.2022.07.014","article-title":"Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis","volume":"77","author":"Tranah","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.03.019_bib58","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/hep.26611","article-title":"Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy","volume":"59","author":"Rockey","year":"2014","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2023.03.019_bib59","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/j.jhep.2020.11.013","article-title":"The microbiota in cirrhosis and its role in hepatic decompensation","volume":"75","author":"Trebicka","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.03.019_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060042","article-title":"Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy","volume":"8","author":"Bajaj","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2023.03.019_bib61","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/apt.12695","article-title":"Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis","volume":"39","author":"Bajaj","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2023.03.019_bib62","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1053\/j.gastro.2014.08.031","article-title":"Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial","volume":"147","author":"Dhiman","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.03.019_bib63","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/hep.30690","article-title":"Fecal microbial transplant capsules are safe in hepatic encephalopathy: a phase 1, randomized, placebo-controlled trial","volume":"70","author":"Bajaj","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.03.019_bib64","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1007\/s10620-019-05576-9","article-title":"Increasing burden of hepatic encephalopathy among hospitalized adults: an analysis of the 2010-2014 National Inpatient Sample","volume":"64","author":"Hirode","year":"2019","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2023.03.019_bib65","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jhep.2014.09.005","article-title":"Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure","volume":"62","author":"Romero-Gomez","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.03.019_bib66","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2013.10.004","article-title":"Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF)","volume":"60","author":"Cordoba","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.03.019_bib67","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jhep.2022.02.010","article-title":"Racial and ethnic disparities in rifaximin use and subspecialty referrals for patients with hepatic encephalopathy in the United States","volume":"77","author":"Tapper","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.03.019_bib68","first-page":"4050","article-title":"New therapies of liver diseases: hepatic encephalopathy","volume":"10","author":"Mangini","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.cgh.2023.03.019_bib69","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40265-018-1024-1","article-title":"LOLA) for hepatic encephalopathy in cirrhosis: results of randomized controlled trials and meta-analyses","volume":"79","author":"Butterworth","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.cgh.2023.03.019_bib70","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhep.2022.09.009","article-title":"A\u00a0double-blind randomized placebo-controlled trial of albumin in outpatients with hepatic encephalopathy: HEAL study","volume":"78","author":"Fagan","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.03.019_bib71","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jhep.2004.12.028","article-title":"Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study","volume":"42","author":"Riggio","year":"2005","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.03.019_bib72","doi-asserted-by":"crossref","first-page":"633","DOI":"10.7326\/M20-0202","article-title":"The use of rifaximin in the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt : a randomized controlled trial","volume":"174","author":"Bureau","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2023.03.019_bib73","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.cgh.2022.05.042","article-title":"Dosing of rifaximin soluble solid dispersion tablets in adults with cirrhosis: 2 randomized, placebo-controlled trials","volume":"21","author":"Bajaj","year":"2023","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356523002276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356523002276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:43:30Z","timestamp":1761543810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356523002276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":73,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1542356523002276"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2023.03.019","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update in the Treatment of the Complications of Cirrhosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2023.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the AGA Institute","name":"copyright","label":"Copyright"}]}}